Posts Tagged ‘colangiocarcinoma’

Categories

Posted in:

Thursday January 22nd, 2015

Two new mutations in cholangiocarcinoma increase the therapeutic possibilities up to a 70%

A study led by researchers from IDIBAPS and funded by the aecc-Cataluña against Cancer in Barcelona has identified, for the first time, two genetic alterations that occur in intrahepatic cholangiocarcinoma (ICCA) and may represent a therapeutic target. Furthermore, they have mapped all the molecular alterations that occur in this type of liver cancer and they have found that 70% of patients have at least one of them. Dr. Josep M. Llovet, ICREA Research Professor at the HCC Translational Research Lab of the Liver Unit at IDIBAPS and Director of Mount Sinai Liver Cancer Program at the Icahn School of Medicine at Mount Sinai (New York), and Dra. Daniela Sia, researcher at the same group, are the principal investigator and the first author of the paper published in the journal Nature Communications. Dr. Josep Fuster, from the IDIBAPS Hepatic Oncology team and Surgery Professor has also participated in the study.

Read the rest of this entry »

Comments Closed

Categories

Posted in:

Thursday July 03rd, 2014

A mutation in progenitor cells identified as origin and therapeutic target for cholangiocarcinoma

In recent years, cancer research has been focused on the identification of mutations in genes involved in tumor development. Nevertheless, the molecular pathways that contribute to the progression of the disease remain quite unknown. The journal Nature publishes a paper in which an international team of scientists, led by Nabeel Bardesy, PhD, from the Harvard Medical School, suggests that a mutation in the IDH enzyme (isocitrate dehydrogenase), that occurs in liver progenitor cells, promotes the progression of cholangiocarcinoma, a type of liver cancer. Josep M. Llovet, MD, PhD, ICREA Research Professor at the HCC Translational Research Lab of the Liver Unit at IDIBAPS and Director of Mount Sinai Liver Cancer Program at the Icahn School of Medicine at Mount Sinai (New York) has collaborated in the study together with Daniela Sia, PhD, and Helena Cornellà, members of the same research group.

Read the rest of this entry »

Comments Closed

Categories

Posted in:

Thursday January 31st, 2013

A research funded by the AECC identifies two molecular types of cholangiocarcinoma, the most aggressive liver cancer

A research, funded with 1.2 million euros by the Spanish Association Against Cancer (AECC) Barcelona – Scientific Foundation, has established the molecular classification (genetic mechanism) of intrahepatic cholangiocarcinoma (ICC). This means an important advance in the search for an effective drug treatment. Today the only available treatment is surgery, and it is applicable only in the early stages of this disease. This cancer is resistant to any therapy and the second most frequent liver tumor. The investigation is led by Dr. Josep María Llovet, President of the International Liver Cancer Association (ILCA) and ICREA research professor at IDIBAPS, where he develops and coordinates most of the study, which has the support of two major international centers for treating liver cancer: Mount Sinai in New York and the National Cancer Institute in Milan.

Read the rest of this entry »

Comments Closed